After Transplant: Finding Qualified Health Care Providers

Celebrating a Second Chance at Life Survivorship Symposium

May 3-9, 2025



Paul Carpenter, MB, BS, BSc Fred Hutchinson Cancer Center



After Transplant: Finding Qualified Healthcare Providers

Celebrating a Second Chance at Life Survivorship Symposium May 3- 9, 2025

Paul Carpenter, MB BS

Medical Director of LTFU
Fred Hutchinson Cancer Center, Seattle
Professor University of Washington, Seattle



Learning Objectives

- The "When", "Why", "What" and "How" of BMT Survivorship or Long-Term Follow-Up (LTFU) Care
 - Care Models and their feasibility
- Goals of BMT Long-Term Follow-Up care:
 - Dr. Carpenter's "Core to the Outer Spheres" for comprehensive Long-Term Follow-Up
- Role of Survivorship Care Plans
- What makes an ideal BMT LTFU healthcare provider?



When does Long-term Follow-Up care begin after BMT?

Phases of the BMT Care Continuum

1

2

3

4

Diagnosis, initial treatment and MD referral to BMT Center

BMT Consult,
Pre-transplant
work up ± donor
search

Conditioning,
BMT and early
post-BMT care at
Transplant Center

quicker recovery if transplant is with own cells ("autologous") vs. donor cells ("allo") LTFU for "Survivors" after Day 100*

*Long-term survivors often considered ≥2 years from BMT



Why is Long Term Follow Up So Important?

Regarding BMT Survivors...

- ~500,000+ in the US by 2030
- 2 in 3 have at least one health condition = double the rate in siblings
- Early detection/prevention aims to prevent significant complications and premature mortality.




Life expectancy in Seattle patients who survived at least 5 Years after their BMT


- 7,984 BMTs through 2002
 - High-dose conditioning
 - 5,410 died within 5 years, relapsed, had a 2nd BMT, or were lost to follow-up
- $2,574 \ge 5$ -year survivors
 - Half were aged 46 years (range, 6-80) at analysis
 - Half were 13 years (range 5-36) post-transplant
 - 80.4% survived 20 years post-transplant





Life expectancy in Seattle patients who survived at least 5 Years after their BMT





Martin et al, JCO 2010



Life expectancy has improved for survivors (\geq 2+ y) over the past 40 years, but mainly for patients age <18 years


- 4,741 BMTs at City of Hope, University of Minnesota, and University of Alabama between 1974 and 2014
- Across the three periods:
 - More older patients received BMT
 - Conditioning got less intense
 - There was more chronic GVHD
- Half were age 12 years post-BMT (range 2-44 y) at analysis

Bhatia et al, JAMA Oncol 2021




Life expectancy after transplant was better in children than in adults

Survival in patients with BMT at age <18



8.5% life expectancy (= 2 years)

Survival in all BMT patients



Overall 20.8% ↓ life expectancy (= 8.7 years)

- 9.7% if no CGVHD (4.4 y)
- **25%** if CGVHD (9.6 y)

Bhatia et al, JAMA Oncol 2021




Leading Cause of Death at 30 years Post-Transplant

- Relapse = 12%
- Infection = 11%
 - 52 times higher than the general population
- Second cancer = 7%
 - 4.8 time higher than the general population
- Cardiovascular = 4.6%
 - 4.1 times higher than the general population
- Lung disease = 2.7%
 - 13.9 times higher than the general population



Good news is that Chronic GVHD is decreasing while survival is increasing for Seattle BMT patients





· · • · · cGVHD-All

Non-relapse deaths


— Survival

→ aGVHD II-IV

Carpenter et al, Blood Adv 2024




Beyond Survival: Why is Long-Term Follow-Up So Important?





Premature Discontinuation of Long-Term Follow-Up is a Problem

Large Japanese Study of BMT survivors: (N = 17,980)



Patients who prematurely ended long-term follow-up:





Why Long-Term Follow-Up was Discontinued

Large Japanese Study of BMT survivors: (N = 17,980)


- Most often, doctor-instigated based on "patient's good physical condition"
- Most likely at-risk are adolescents and young adults but also:
 - BMT for non-malignant disease or standard-risk malignancy
 - Those without chronic GVHD




Long-Term Follow-Up Differs after a Transplant With Your Own Cells (Autologous) versus a Transplant with Donor Cells (Allogeneic)!



Autologous Stem Cell Transplant: LTFU Timeline



Allogeneic Stem Cell Transplant: LTFU Timeline



Why is Chronic GVHD Such a Burden?

- Moderate/Severe chronic GVHD is associated with worse quality of life, higher symptom burden, pain medication use, and depression.
- 1-in-4, to 1-in-3 people with active chronic GVHD are unable to work compared to one-in-eight with resolved chronic GVHD
- Caregivers have more depression and sleep disorders than the general population
- Patients with chronic GVHD have 4-5 times the rate of moderately severe to life-threatening health conditions than their siblings.

Lee et al, Haematologica 2018 Jamani et al, BBMT 2018 Sun et al, Blood 2010



Some Causes of Late Effects

Complications by organ (representative example)	Chronic GVHD or its therapies	Conditioning	Infection
Ocular: (dry eyes)	+++	++	+/-
Oral: (dry mouth)	+++	++	+/-
GI tract: (late dysphagia)	++	-	+/-
Liver: (elevated ALT/AST and/or alkaline phos)	+++	-	++
Lung: (airflow obstruction)	++	+	++
Bone: (decreased bone mineral density or AVN)	+++	+	-
Endocrine: (secondary adrenal insufficiency)	+++	-	+/-
Metabolic: (insulin resistance, hypertension)	+++	+/-	+/-
Musculofascial: (myopathy/myositis)	+++	-	+/-
Vulvovaginal: (erythema, erosions)	+++	-	+
Rare: (myasthenia gravis)	+	-	-



20-point Head-to-Toe Long-Term Follow-Up List


ORGAN-ba	sed
1.Ocular	FA
2. Ear	FA
3. Oral	FA
4. Lung	
5. Heart	FA
6. GI / hepa	tic
7. Musculo- skeletal	FA
8. Renal / G	U FA
9. Skin	FA

	SYSTEMS-based	
10. Graft/chimerism		
11.	Immunity	
12.	Endocrine/ metabolic	FA
13.	Neurocognitive	FA
14.	Psychological	FA

PROBLEM-based
15.Chronic GVHD
16.Infection
17. Infertility FA
18. Iron Overload FA
19. Quality of life FA
20. Subsequent FA
Neoplasms



Always consider 1-20 via the lens of underlying disease indication for transplant








LTFU Providers need to organize this List

- LTFU care plans have core elements for every survivor.
- After Allo-transplant, providers should diligently conduct chronic GVHD screening exams every 1-2 months during and up to 1 year after tapering immune suppressive therapy
- LTFU care plans are also individualized and prioritized accordingly
- My approach is to consider the following spheres of evaluation...



Dr. C's "Core to Outer Spheres for Comprehensive LTFU"



- Core elements
- Bone health, thyroidChildren: growth/pubertyAdults: fertility/menopause
- Lungs, heart, kidneys, eyes, liver, GI tract, brain
- BMI, Blood pressure, urinalysis, nutrition, fasting metabolic labs
- Skin, oral, breast, colon, others if genetic risk or predisposition syndrome
- At a minimum, screen annually

How is Long-Term Follow-Up Best Conducted?



BMT Long-Term Follow-Up Survey American Society for Transplant and Cellular Therapy (ASTCT)

- ~5,000 accredited US hospitals: ~177 (3.5%) contain a BMT center
- Survey response rate 38.5%:
 - 45% had an LTFU clinic
 - ≥85% agreed Nurse Practitioners/Physician Assistants were essential
 - allo-BMT survivors should be seen lifelong
 - clinics help provide preventive guidelines
 - 55% had no LTFU clinic
 - only 28% felt they had too few patients to establish one.
 - 100% agreed allo-BMT survivors have needs separate from GVHD, and transitions of care (peds to adult, or away from transplant center) can lead to complications.
 - 84% prefer to provide survivorship care as individual practitioners

Hashmi et al, BBMT 2018




Obstacles to LTFU Clinics

- Lack of Expertise
- Logistics (space, infrastructure, commitment)
- Fiscal
- Preference for individual practitioner continuity care model



Availability of Sub-Specialists at BMT Centers with Long-Term Follow-Up Clinics





Model of LTFU Care Often Depends on HCT Center Size

Large Centers

>500 HCT/yr


A. Dedicated LTFU Dept.

Expert LTFU
Providers rotate

B. LTFU
Continuity Clinics

No rotation

 $C_{\cdot} = A + B$





Smaller Centers

100-200 HCT/yr

Continuity Clinics

≤50 HCT/yr

Individual provider follows a small patient panel



Models of LTFU Care: Center with <30 BMT per year

"Jack-of-all-Trades"

Single Provider

Diagnosis, initial treatment and MD referral to BMT Center BMT Consult,
Pre-transplant
work up ± donor
search

Conditioning, BMT and early post-BMT care at Transplant Center

LTFU for "Survivors" after Day 100*

Pros	Cons
Better Continuity	Harder to develop depth of chronic GVHD "playbook scenarios at smaller center"
Easier to establish Rapport	Minimal to no chronic GVHD subspecialty expertise
Efficiency via legacy of Continuity	"Jack-of-all-Trades" maybe too stretched to do justice for chronic GVHD/LTFU patients
Patients and Providers often prefer this model	Limited experience with full range of Late Effects



Models of LTFU Care: Center with ≥100-200 BMT/yr

Diagnosis, initial treatment and MD referral to BMT Center

BMT Consult, Pre-transplant work up ± donor search Conditioning, BMT and early post-BMT care at Transplant Center

LTFU for "Survivors" after Day 100*

Leverages Non-BMT
Cancer Survivorship Clinic

Subspecialties are available

Pros	Cons
Continuity can vary from moderate to high	Easier to develop reasonable chronic GVHD "playbook scenarios" depending on continuity model
Subspecialties more available	Chronic GVHD subspecialty expertise still variable
This model can work well for autologous transplants because no GVHD	Busy clinics may have insufficient time for comprehensive chronic GVHD exams
Higher access to cutting edge chronic GVHD therapies on research studies vs small center	Variable experience with full range of Late Effects
Patients / Providers often prefer a continuity model	



Models of Long-Term Follow-Up Care: Centers with ≥500 BMT/year


Diagnosis, initial treatment and MD referral to BMT Center BMT Consult, Pre-transplant work up ± donor search Conditioning, BMT and early post-BMT care at Transplant Center LTFU for "Survivors" after Day 100* More often have dedicated BMT LTFU

Relevant subspecialties

Pros	Cons	
Continuity suffers in rotational models	Harder to maintain rapport in rotational model for patients with cGVHD	
Deep knowledge of cGVHD	Limited capacity if large survivor panels	
Full Spectrum of Subspecialties	Finite capacity limits in-person consultations to more complex patients or annually	
Highest access to cutting edge cGVHD research therapeutics	Hospital administrators need convincing why longer clinic visits are necessary	
Telemedicine can assist management in remote hometowns	Mostly unbillable	



What about patients far away from NCI-designated Comprehensive Cancer Centers?



Drivetimes to Seattle from

- Spokane: 4-5 hours
- Tri-Cities: 3.5-4 hours (If not snowing!)
- Even harder to get to from remote, smaller towns!

How to address this?

- Telehealth
- Outreach clinics

Long-Term Follow-Up Models of Care

A. No LTFU Clinic (Traditional)



Jack-of-All-Trades

- Soley responsible for patient panel
- Small TC option

B. Shared Cancer Survivorship Clinic (CSC)



- Transplant center continuity provider leverages CSC infrastructure
- Tend to lack CGVHD expertise relative to C


C. Dedicated BMT LTFU Clinic




- Rotating BMT LTFU Experts
- Breadth of subspecialties
- Limited Capacity (e.g. 6000 prevalent survivors at Fred Hutch)


Communication Approach

Traditional



Collaborative





Does Telemedicine Help Patients Who Live Far from Their BMT Center?

...we think probably yes but need to study it more!

- Seattle study found no impact of distance or urban/rural residence on clinical outcomes
- CIBMTR registry study reported good survival after chronic GVHD for low-risk (group 1) patients but step-downs in survival for higher-risk groups 2 to 6, fully explained by step-ups in non-relapse deaths
- In contrast, a Seattle Study showed better survival for higher-risk groups explained by no increment in non-relapse deaths, possibly attributed to the dedicated LTFU program and robust telemedicine

 Khera et al, BBMT 2016



What about Survivorship Care Plans?

• A randomized trial tested whether survivorship care plans <u>mailed</u> to transplant survivors and created by the Center for International Blood & Marrow Transplant Research (CIBMTR) improved confidence in survivorship info at 6 months compared to baseline (based on phone surveys with ~87% completion rate)

495 survivors at 1-5 years post-BMT→ 37 did not complete baseline survey





Did Survivorship Care Plans Help?

- Survivorship Care Plans did <u>not</u> improve confidence in
 - survivorship info
 - knowledge of BMT exposures
 - health care utilization
- Survivorship Care Plans <u>did</u> reduce treatment distress and the mental aspects of quality of life
- While Survivorship Care Plans are generally considered valuable, more work needs to be done!



ASTCT Long-Term Follow-Up Survey: Conclusions

- One-size-fits-all clinic specifications are not feasible:
 - Center size, resources vary widely
 - The relative merits of shared long-term follow-up clinics (integrating single continuity providers) vs. centralized clinics (rotational provider model) are unclear
 - Need to accommodate survivors at distant locations from the transplant center.
- We need to figure this out!



Characteristics of the Ideal BMT Long-Term Follow-Up Healthcare Provider

- Committed to the needs of this population and critically understands that:
 - Early detection of chronic GVHD is vital to survivors' quality of life and even life expectancy
 - Late effects have latency, and survivors need annual follow-up even if they "look fine"
 - Focus on "core elements" is critical, with "Dr. C's outer spheres" tackled at least annually
- Conducts robust monthly symptom evaluation, exams, and medication reconciliation
- Authentically commits to collaborative communication with the Transplant Center
 - Timely and thorough bidirectional responses are key!



Barriers to Finding the Ideal BMT Long-Term Follow-Up Healthcare Provider

- Not all patients live close to a transplant center, let alone a highvolume one experienced in chronic GVHD management.
- Bandwidth of some providers is so stretched that there can be insufficient time to address even the "core elements" – especially thorough exams to check for GVHD
- Non-reimbursement for time spent communicating with Transplant Center
- Not all transplant centers have a well-developed telemedicine service



Long-Term Follow-Up Takeaways

- LTFU starts 60-100 days post-BMT and is more complex after allo-HCT (cGVHD)
- LTFU Care Models vary by transplant center size, feasibility, MD preference, patient hometown location, and resources; a one-size-fitsall approach is unlikely
- Comprehensive BMT LTFU care starts with core elements, then moves to other aspects, always considering patient exposures, genetics, lifestyle, mood, and quality of life.
- Survivorship Care Plans reduce distress but determining their larger role needs more work – referring MDs prefer concise to-do list over

Long-Term Follow-Up Takeaways, cont'd

- Survivorship Care Plans reduce distress but determining their larger role needs more work
 - referring MDs prefer a concise to-do list over multiple-page reports
- Telemedicine ± and perhaps Outreach Clinics are likely key elements to delivering LTFU to a growing number of BMT survivors spread far and wide



Questions?



Paul Carpenter, MB, BS, BSc Fred Hutchinson Cancer Center



Let Us Know How We Can Help You



Visit our website: bmtinfonet.org

Email us: help@bmtinfonet.org

Phone: 888-597-7674 or 847-433-3313

